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Abstract 
This systematic review updates a systematic review that synthesized inorganic arsenic 
exposure and respiratory health effects published in 2016. The final review added eight 
publications from six countries. It examined the relationship between inorganic arsenic exposure 
and five respiratory outcomes, including lung function, respiratory symptoms, acute respiratory 
infections, chronic respiratory disease, and non-malignant lung disease mortality. Emerging 
evidence showed a general association between InAs and non-malignant respiratory illnesses, 
including consistent evidence on lung function impairment, respiratory symptoms, acute 
respiratory tract infections, and non-malignant lung disease. Early life InAs exposure has lasting 
effects on the respiratory system throughout the lifespan. This review found some research gaps, 
including mixed evidence of sex differences, limited evidence at low-level exposure (water 
arsenic<100 μg/L), and uncertainty on pathogenic mechanisms in response to arsenic exposures. 
Limitations including potential publication bias, potential language bias, incomplete exposure 
histories, ecological fallacy, and non-comparability of outcome measures across publications. 
The public health significance of this systematic review is providing more robust 
epidemiologic evidence. It could be helpful and instructive for future research on the detrimental 
effects of arsenic on respiratory health. 
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1.0 Introduction 
Inorganic arsenic (InAs) is listed as one of 10 chemicals of primary public health concern 
by the World Health Organization (WHO) (Organization, 2010b). Arsenic exposure threatens the 
health of millions of people around the world through the consumption of naturally contaminated 
groundwater or food (Organization, 2010a). Inorganic arsenic naturally occurs at high levels in the 
groundwater (wAs) of many countries, including Argentina, Chile, China, India (West Bengal), 
Mexico, the United States and particularly Bangladesh, which above the WHO provisional 
guideline value of 10 μg/L (Organization, 2010a). The International Agency for Research on 
Cancer lists arsenic in drinking water as a type 1 lung carcinogen, meaning there is sufficient 
evidence to conclude that arsenic in water causes lung cancer (Straif et al., 2009). Arsenic’s non-
malignant lung effects have been less well studied than its lung cancer effects, but results of several 
human epidemiologic studies suggest deleterious effects of arsenic on a variety of non-malignant 
pulmonary outcomes, including impaired pulmonary function, respiratory symptoms, airway 
epithelial damage, chronic obstructive pulmonary disease (COPD), and tuberculosis (D. N. 
Mazumder et al., 2000; D. N. Mazumder et al., 2005; Milton, Hasan, Rahman, & Rahman, 2003; 
Milton & Rahman, 2002; Parvez et al., 2008; Rahman, Vahter, Ekstrom, & Persson, 2011; Smith 
et al., 2006; Smith et al., 2011). There is also growing evidence linking arsenic to non-malignant 
respiratory diseases (Tiffany R Sanchez, Perzanowski, & Graziano, 2016).  
However, only two review articles on InAs and non-malignant lung disease were published 
in 2007 (D. G. Mazumder, 2007) and 2016 (Tiffany R Sanchez et al., 2016). (Tiffany R Sanchez 
et al., 2016) identified twenty-nine articles that examined the relationship between inorganic 
arsenic exposure and respiratory outcomes. They found strong evidence of a correlation between 
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arsenic and non-malignant respiratory illness, including consistent evidence of lung function 
impairment, respiratory symptoms, acute respiratory tract infections, and non-malignant lung 
disease mortality. This review aims to synthesize the additional research on InAs and respiratory 
health effects that have been published since 2016, based on a systematic review of the literature 
from 1998 through 2015 (Tiffany R Sanchez et al., 2016). 
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2.0 Methods 
2.1 Search Strategy 
This review's search strategy followed the PRISMA guidelines (Moher, Liberati, Tetzlaff, 
Altman, & Group, 2009). Systematic searches were conducted in two bibliographic databases, 
including EMBASE and PUBMED. A Gray literature search was conducted with Google Scholar. 
For bibliographic databases, searched were conducted combining comprehensive English 
terms representing non-malignant respiratory health effects with terms for InAs exposure with the 
Boolean operator AND (See supplementary material for a complete list of search terms, (Tiffany 
R Sanchez et al., 2016)). I used both keywords and MeSH terms/ emtree terms to search PubMed 
and EMBASE between January 2016 to April 2020 with English-language restrictions. To be 
included, articles had to meet the following a priori criteria: “ (1) included original human-based 
research published in a peer-reviewed journal; (2) had a control or referent group; and (3) inclusion 
of an indicator of InAs exposure studied related to any one or more of the following outcome 
categories listed in Table 1” (Tiffany R Sanchez et al., 2016). 
Search results were downloaded using Endnote and subsequently screened title and 
abstract. Articles that meet the initial screening stage were reviewed in full text by all authors. 
During the full-text review, whether multiple publications from the same study population 
contained duplicate data were assessed. Various publications of the same study were identified by 
checking author affiliation, study design, cohort name, enrollment criteria, and enrollment dates. 
When multiple articles were reporting on the same study, the relevant literature and noted possible 
overlaps in the results section would be reviewed. 
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2.2 Data Abstraction 
For publications that categorized exposure of outcome, evidence from the highest category 
vs. the lowest category was put forward. Additional subgroup analyses were performed on (1) 
critical exposure periods; (2) gender differences; and (3) low-level InAs exposure (wAs < 100 
μg/L) (Tiffany R Sanchez et al., 2016). All subgroup analyses were specified a priori.  
2.3 Quality Assessment 
Quality appraisal criteria were based on existing systematic reviews on InAs exposure 
(Navas-Acien et al., 2005; Tiffany R Sanchez et al., 2016; Zheng et al., 2014). Quality assessment 
questions fall into five categories: exposure assessment, outcome assessment, statistical analysis, 
data collection, and specific questions for longitudinal studies. The exposure assessment for each 
study is also described in more detail in the results subsection. All authors independently evaluate 
the quality and risk of bias for each article. Together, the authors resolved all disagreements and 
discussed the potential risks of any biases that might be overlooked. 
 
 
 
 
 
 
 
 5 
 
Table 1 Eligibility criteria objectives are pre-created using an adaptive PICOS format 
Topic Question Exclude if 
Participants 
Exposure 
 
Comparisons  
 
Outcome 
 
 
 
Study design 
Are the study participants human? 
Does the article have a relevant exposure 
measurement? 
Does the article have a control or referent group? 
 
Does the article have a relevant outcome (i.e., 
lung function, respiratory symptoms, acute 
respiratory infections, chronic non-malignant lung 
disease, and non-malignant respiratory mortality)? 
Does the article report primary data? 
Not human 
No measure of exposure (or occupationally 
/ATO Chemotherapy exposed) 
No reference group (i.e., case study or case 
report) 
Not relevant 
 
 
 
No primary data 
Note. Reprinted from “Inorganic arsenic and respiratory health, from early life exposure to sex-specific 
effects: A systematic review,” by Sanchez, T. R., Perzanowski, M., & Graziano, J. H. (2016), 
Environmental Research, 147, 537-555.  
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3.0 Results 
3.1 Overview 
The results from my systematic search are outlined in Fig. 1. A total of 1174 articles were 
identified from two databases, resulting in 1094 unduplicated articles. Following a screening of 
titles and abstracts, 36 articles were selected for full-text review. The final review included eight 
publications from six countries. Two publications were from the USA, two were from Bangladesh, 
two were from Chile, and one from Turkey and China. Articles were published in seven different 
journals between 2016 and 2020. Six publications were cross-sectional studies, and two were 
longitudinal studies.  
Several publications reported multiple related endpoint categories:  eight publications 
examined lung function, four examined respiratory symptoms, one examined acute respiratory 
infections, one examined acute respiratory infections, and two examined chronic respiratory 
disease. 
3.1.1  Sub-analyses of interest 
Three articles examined the effects of utero InAs exposure at different life stages, including 
endpoints during childhood (Ahmed et al., 2017a), and adulthood (Nardone et al., 2017; 
Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016). Two 
publications stratified their results by sex (Ahmed et al., 2017a; Shih, Argos, & Turyk, 2019). Two 
publications examined the effects of InAs<100μg/L (Powers et al., 2019; Shih et al., 2019). 
 7 
 
Figure 1 Publication selection process 
3.1.2  Quality assessment 
Fig.2 shows an overview of the quality assessment for each publication. Each result 
subsection for the selected publications applied a more rigorous quality evaluation. 
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Five publications evaluated InAs exposure at the individual level. The other three assessed 
InAs exposure ecologically. Most publications had either incomplete exposure histories or did not 
include exposure from all major sources (water and diet). In general, publications with a history 
of incomplete exposure measured either current urinary arsenic (uAs) or wAs measurements 
(and/or recent exposure history) but had no record or a history of early life exposure. Alternatively, 
publications had prenatal/early life InAs exposure measurements but did not have later life 
exposure/ exposure measurement in conjunction with the outcome. Therefore, publications that 
use early exposure markers do not necessarily include all major sources of exposure throughout 
the life course. Besides, as a vital factor of exposure, the InAs exposure in the diet is getting more 
and more attention, especially in the case of a low level of InAs in drinking water. Thus, 
publications that used exposure biomarkers and reported previous InAs exposure levels (including 
lifetime exposure levels) had an assessment of higher quality exposure than publications that 
classified InAs exposure only on the basis of wAs levels or used isolated uAs measurements. 
Most studies standardized respiratory symptom questionnaires and lung function 
measurements; however, most chronic lung disease outcomes were self-reported. Diagnostic 
criteria for several outcomes (including chronic bronchitis and pneumonia) were inconsistent in 
various publications, thus increasing uncertainty of the results of classification (respiratory 
symptoms versus acute respiratory infections and chronic respiratory diseases) and making 
comparisons between publications challenging. 
Most publications showed the internal comparison between the study group. Most 
publications also fully controlled the important potential confounding factors, including age, sex, 
and smoking. Different publications reported differently on the selection criteria and participation 
rates of participants.  The participant rates were generally adequate. The two cohort publications 
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both reported follow-up rates and described how those lost to follow-up. It was often unclear 
whether the interviewer was blinded to the exposure status of the person interviewed. Only two 
publications reported both adjusted and unadjusted results. The accumulation of strength of the 
evidence about InAs and non-malignant lung disease was attenuated by these methodological 
limitations. In summary, this systematic review includes articles of both high quality (reliable 
exposure assessment, adjusted potential confounders and standardized outcome measures) and low 
quality (incomplete exposure assessment/history, no adjustment for potential confounders, and 
non-standardized outcome indicators). 
 
 
Figure 2 Quality assessment at the publication level 
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Was the exposure marker assesed using a biomarker or water arsenic at the individual-level?
Was an appropriate latency period considered?
Were all major exposure sources/time points included?
Was exposure assessment independent of disease status?
Were outcomes based on objective tests of standardized criteria in ≥90% of study participants？
Did the authors present internal comparisons within study participants?
Did the authors control for potential confounding risk factors in addition to age?
Were other potential confounders (i.e.smoking) appropriatedly measured and accounted for?
Were appropriate statistical methods used?
Are both adjusted and unadjuste results given?
Did participation rates include those who declined, provided inadequated data or other exclusions? .. .. ..
Were the participation rates adequate (e.g.>70%)? .. .. ..
Were the data collected in a similar manner for all participants?
Where the same exclusion criteria applied to all participarts? .. .. ..
Was the time period over which exposed/unexposed interviewed the same? .. .. ..
Was the interviewer blinded with respect to the exposure status of the person interviewed?
Longitudinal Studies:
Were follow-up rates adequate? .. .. .. .. .. ..
Were there nominal differences in follow-up rates based on disease and exposure status? .. .. .. .. .. ..
legend: Yes No/unknown .. N/A
10 
Table 2 Evidence table on InAs and lung function 
Reference 
Study design 
Location 
Size 
Age(yrs) 
male 
Exposure level Outcome Effect estimate 95% CI/ 
p-Value 
Comments 
Ecological-level water arsenic publications 
(Steinmaus, Ferreccio, 
Acevedo, Balmes, Liaw, 
Troncoso, Dauphine, et 
al., 2016) 
 
Cross-sectional 
Chile 
 
n=795 
Exp: in utero 
Out: Adults 
Male: 51 
wAs:<11 
 
vs. 
wAs>200 
FVC (mL) 
FEV1 (mL) 
Mean Diff -224          -351, -29 
Mean Diff  -64           -174, 47 
Among non-smokers with 
the highest single-year 
arsenic water 
concentrations. Adj: 
smoking (in smokers) and 
Aymara race 
(Nardone et al., 2017) 
 
Cross-sectional  
Chile 
 
n=751 
Exp: in utero 
Out: Adults 
Male: 45 
wAs<11 
vs. 
wAs: 11-200 
FVC (mL) 
FEV1 (mL) 
FEV1/FVC 
Mean Diff  -59           p=0.07 
Mean Diff -27            p=0.69 
Mean Diff 0.80          p<0.004 
For lifetime highest single 
year exposure. Unadjusted. 
(Siddique et al., 2020)  
 
Cross-sectional 
  
Bangladesh 
 
n=842 
Exp: Adults 
Out: Adults 
Male:51.1 
wAs: 0.03-5.3 
vs. 
wAs: 135-1800 
FEV1 (mL) 
FEV6 (mL) 
FEV1/FEV6 
Association -0.203     p<0.003 
Association -0.169     p<0.019 
Association -0.055     p<0.001 
Adj: age, sex, BMI, 
smoking habits, income, 
education and occupation 
 
Urinary arsenic publications 
 (Ahmed et al., 2017b) 
 
Longitudinal 
Bangladesh 
 
n=540 
Exp: in utero  
Out: 9 
Male:49 
uAs>150 
vs. 
uAs<50 
FVC (mL) 
FEV1 (mL) 
       
Mean Diff -79          -159, 0.5 
Mean Diff -76          -154, 2.1 
 
Adj: age, HAZ, SES, sex, 
season, mothers’ 
education, plasma 
concentrations of CRP, and 
maternal micronutrient 
supplementation groups. 
 
(Gunduzoz et al., 2018) 
 
Cross-sectional 
Turkey 
 
n=150 
Exp: Adults 
Out: Adults 
Male: 100 
 
uAs: 2.5-246 
vs. 
uAs: 0.1-6 
FVC (%) 
FEV1 (%) 
FEV1/FVC 
FEF25-75 (%) 
                   (-)          p<0.001 
                   (-)         p<0.001 
                   (-)          p<0.001 
                   (-)          p<0.001 
Adj: age, work years, 
gender, smoking and race. 
(Powers et al., 2019) 
 
Longitudinal 
 
USA 
 
n=2132 
Exp: Adults 
Out: Adults 
Male: 40 
uAs>16.7 
vs. 
uAs<5.8 
FEV1 
(%pred) 
 
FVC (%pred) 
Mean Diff -1.39       -2.51, -0.25 
 
 
Mean Diff -1.13       -2.21, -0.05 
Adj: age, sex, education, 
study site, smoking status, 
smoking pack-year, eGFR, 
tuberculosis, and BMI. 
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Table 2 (continued) 
Reference 
Study design 
Location 
Size 
Age(yrs) 
male 
Exposure level Outcome Effect estimate 95% CI/ 
p-Value 
Comments 
(Shih et al., 2019) 
 
 
Cross-sectional 
USA 
 
n=3626 
Exp: Adults 
Out: Adults 
Male: 50 
uAs<5.61 
  
vs. 
uAs: 6.0-6.4 
FVC (mL) 
FEV1 (mL) 
FEF25-75 
(mL/s) 
Mean Diff -45.15     -126.76, 36.45 
Mean Diff  -69.40    -133.73, -5.06 
Mean Diff -125.06   -229.30, -
20.82 
Among non-smokers with 
the highest single-year 
arsenic water 
concentrations. Adj: 
smoking (in smokers) and 
Aymara race 
Hair arsenic publication 
(Wang, Wang, Zou, 
Zheng, & Zhang, 2020) 
 
Cross-sectional 
 China 
 
 
n=292 
Exp: Adults 
Out: Adults 
 
Male: 61.3 
hAs: 0.09-0.19 
vs. 
hAs: 0.18-0.39 
FVC (%) 
FEV1(%) 
FEF25 (%) 
FEF50 (%) 
FEF75 (%) 
FVC/FEV1 
Mean Diff -3.26          p<0.05 
Mean Diff -2.73  p<0.05 
Mean Diff -8.43 p<0.05 
Mean Diff -6.20 p<0.05 
Mean Diff -6.19 p<0.05 
Mean Diff -0.03 p>0.05 
Among those without skin 
lesions. 
Adj: age, gender, BMI, 
smoking, and alcohol 
consumption. 
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3.2 Lung Function 
Eight publications evaluated the relationship between InAs and lung function. (Ahmed et 
al., 2017a; Gunduzoz et al., 2018; Nardone et al., 2017; Powers et al., 2019; Shih et al., 2019; 
Siddique et al., 2020; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 
2016; Wang, Wang, Zou, Zheng, & Zhang, 2020). Table 2 shows the relationship between InAs 
and three spirometric outcomes used to measure lung function commonly: forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC) and the ratio of FEV1 to FVC 
(FEV1/FVC), and other spirometric outcomes including forced expiratory volume in 6 second 
(FEV6), the ratio of FEV1 to FEV6 and The mid-expiratory flow rate (FEF25–75%).  
3.2.1  Strength of the evidence 
Spirometry is a common and effective pulmonary function test (PFT). Seven of eight 
publications used American Thoracic Society (ATS) criteria (Miller et al., 2005) to evaluate 
spirometry acceptability (Ahmed et al., 2017a; Gunduzoz et al., 2018; Nardone et al., 2017; Powers 
et al., 2019; Shih et al., 2019; Siddique et al., 2020; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, 
Troncoso, Dauphine, et al., 2016). The direction of the correlation between InAs and lung function 
was consistent. Eight reported point estimates had four found in the publications of FVC in 
statistically significant decline, and five found a statistically significant decrease in FEV1. 
In the four articles using ATS criteria and reporting raw values, the trend between the 
increase of InAs concentration and the decrease of FEV1 and FVC is consistent. (Steinmaus, 
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Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphiné, et al., 2016), a cross-sectional PFT study 
analysis among 795 northern Chilean adults, found that among never-smokers with highest single-
year arsenic water concentrations of >200μg/L, had adjusted FVC residuals of -224mL and 
adjusted FEV1 residuals of -64mL respectively, compared to those exposed to wAs<11 μg/L. 
Although the exposure assessment was based on wAs levels measured at enrollment time, 
participants were all born and lived at least 80% of their lives in their respective cities. (Nardone 
et al., 2017), a cross-sectional PFT study analysis among 751 northern Chilean adults, found that 
among participants with a single year lifetime highest arsenic exposure of 11-200 μg/L were 
associated with a 59 ml (p=0.07) decrease in FVC and a 27 ml (p=0.69) decrease in FEV1, 
respectively, compared to those never exposed to arsenic concentrations ≥11 μg/L. However, the 
results did not reach statistical significance. (Siddique et al., 2020), a cross-sectional PFT study 
analysis among 842 Bangladesh adults, found that adjusted for age, sex, BMI, smoking habits, 
income, education and occupation, participants with a high concentration of wAs exposure of 135-
1800 μg/L showed a significant negative association with FEV1 (p<0.003) compared to the low 
group of wAs (water As range=0.03-5.3). Results for hair As and nail As were similar. (Ahmed et 
al., 2017a), a longitudinal PFT analysis among a sample size of 540 Bangladeshi children at nine 
years of age, found that adjusted for age, HAZ, SES, sex, season, mothers’ education, plasma 
concentrations of CRP, and maternal micronutrient supplementation groups, high exposed group 
(>150 μg/L at all three-time points) had a 79 mL and 76 mL reduction of FVC and FEV1, 
respectively, compared to low exposed group (<50 μg/L at all three-time points), although the 95% 
confidence intervals included the null value. 
Whereas FVC and FEV1 values are known to differ by ethnicity, the FEV1/FVC ratio is 
independent of the ethnic group (Quanjer et al., 2012). Four publications reported on InAs and 
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FEV1/FVC (Ahmed et al., 2017a; Gunduzoz et al., 2018; Nardone et al., 2017; Wang et al., 2020). 
(Gunduzoz et al., 2018)A longitudinal analysis among 150 Turkey males found the FEV1/FVC 
ratio was significantly lower in firefighters compared to non-exposed male office workers 
(p<0.001). (Wang et al., 2020), a cross-sectional PFT study analysis among 292 Chinese adults, 
found that adjusted for age, gender, BMI, smoking, and alcohol consumption, there were no 
statistical differences in the FVC/FEV1(%) values (Z=-0.03, p>0.05) of the As-exposed and 
reference groups. (Ahmed et al., 2017a) described an inverse association between maternal U-As 
and FEV1/FVC ratio, although the association did not reach statistical significance. (Nardone et 
al., 2017) explained that participants with a single year lifetime highest arsenic exposure below 11 
μg/L and a single year lifetime highest arsenic exposure of 11-200 μg/L had corresponding 
FEV1/FVC ratios of 0.78 and 0.80. The p-value for the difference in the mean FEV1/FVC ratio 
between arsenic exposure<11 μg/L and arsenic exposure of 11-200 μg/L was 0.004.  
3.2.2  Early life exposure 
Few studies have been able to capture all the main sources of exposure from pregnancy to 
adulthood. Although this for any epidemiologic study is an extremely challenging aspect, there 
were three publications had evidence of exposure from early life (Ahmed et al., 2017a; Nardone 
et al., 2017; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphiné, et al., 2016). 
(Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016) and (Nardone 
et al., 2017) both had convincing historical evidence of early life exposure. Here, exposure history 
was based on participants’ long-term residence in either Arica, Iquique, or Antofagasta, Chile. 
Arsenic water concentrations in Iquique and Arica have always remained 8-10 and 60 μg/L, 
respectively. In contrast, Antofagasta has a distinct period of very high arsenic water 
15 
concentrations of about 860 μg/L but dropped about 100 μg/L later. All study participants were 
born between 1958 and 1970, a period of high exposure for Antofagasta. (Ahmed et al., 2017a) 
examined a population of Bangladeshi children aged nine years old, arsenic exposure was assessed 
through urine collected from early pregnant mothers and their children aged 4.5 and 9 years. 
Maternal uAs was inversely associated with FVC and FEV1 in all children. In sum, these three 
publications suggest that early life exposure to InAs was particularly harmful to lung function. 
3.2.3  Sex difference 
Two articles presented sex-stratified results (Ahmed et al., 2017a; Shih et al., 2019). In 
(Shih et al., 2019), the expected changes of FVC and percent predicted values of FVC were lower 
among women than among men, and the expected changes of FEV1 and percent predicted values 
of FEV1 were lower among men than among women; however, evidence was not consistent, which 
may be explained by the low arsenic exposure levels. In (Ahmed et al., 2017a), early life InAs 
exposure was significantly associated with lower FVC and FEV1 among boys. Among girls, the 
direction of association was consistent but not significant.  
3.2.4  Dosimetry 
Two articles evaluated the trend of exposure-response of InAs and lung function (Ahmed 
et al., 2017a; Wang et al., 2020). In (Ahmed et al., 2017a), an exposure-response relationship was 
found between the increasing level of maternal uAs at gestational week eight and decreasing levels 
of FVC and FEV1. (Wang et al., 2020) also found an inverse exposure-response trend between H–
As and FEV1(%), FEV1/FVC (%) and FEF75 (%) (all P < 0.05).  
16 
3.3 Respiratory Symptoms 
Four articles evaluated the relationship between InAs and respiratory symptoms. Articles 
evaluated symptoms separately or in combination and reported from one to five different 
symptom-related endpoints. Three of the four articles on InAs and respiratory symptoms reported 
a statistically significant positive correlation between InAs and at least one respiratory symptom 
(Nardone et al., 2017; Siddique et al., 2020; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, 
Troncoso, Dauphine, et al., 2016). A publication, however, did not find any significant relationship 
between InAs and respiratory symptoms assessed (Powers et al., 2019). Table 3 showed the 
associations between the most commonly reported endpoints, chronic cough, shortness of breath, 
and "any respiratory symptom." 
Table 3 Evidence table on arsenic and respiratory symptoms 
Reference 
Study 
design 
Location 
Size 
Age 
(yrs) 
Male 
(%) 
Exposure 
level 
Outcome Sex Effect 
estimate 
95%CI 
 
Comments 
Ecological- level water arsenic publications 
(Steinmaus, 
Ferreccio, 
Acevedo, 
Balmes, 
Liaw, 
Troncoso, 
Dauphiné, et 
al., 2016) 
 
Cross-
sectional 
Chile 
 
 
n=795 
 
 
 
 
 
 
 
Exp: in 
utero 
 
Out: 
Adults 
Male: 
51 
 
 
 
 
 
wAs>200 
 
vs. 
wAs<11 
 
 
 
 
 
 
 
Dyspnea 
 
Chronic 
cough 
 
 
 
 
 
 
 
All  
 
All 
 
 
 
 
 
 
 
 
Odds 
ratio 5.56 
 
Odds 
ratio 12.0    
 
 
 
 
 
 
2.68, 
11.5 
 
4.47, 
32.0 
 
 
 
 
 
 
For lifetime 
highest single 
year exposure. 
Adj: age, 
gender, 
smoking. 
 
 
 
 
(Nardone et 
al., 2017) 
 
Cross-
sectional 
 
 
 
 
Chile 
 
 
n=751 
 
 
 
 
 
 
Exp: in 
utero 
 
Out: 39-
60 
Male: 
45 
 
 
 
wAs>200 
 
vs. 
wAs<11 
 
 
 
 
 
 
Any 
symptom 
 
Cough 
 
Dyspnea 
 
 
 
 
All 
 
 
All  
 
All  
 
 
 
 
Odds 
ratio 4.07 
 
Odds 
ratio 10.6 
Odds 
ratio 
4.47 
 
2.15, 
7.70 
 
3.24, 
29.2 
 
1.87,10
.7 
 
 
For lifetime 
highest single 
year exposure. 
Adj: sex, age, 
and smoking 
by categories 
of arsenic 
exposure and 
BMI. 
 
17 
(Siddique et 
al., 2020) 
 
Cross-
sectional 
Bangladesh 
 
 
n=842 
Exp: 
Adults 
 
Out: 
Adults 
Male: 
51 
wAs:0.03-
5.30 
vs. 
wAs: 135-
800 
Asthma-
like 
symptoms 
All 
A 
 
L 
 
Odds 
ratio 2.90 
1.90, 
4.43 
Presence of 
one symptom: 
wheezing, 
coughs, 
dyspnea, and 
chest 
tightness. Adj: 
age, sex, BMI, 
smoking 
habits, 
income, 
education, and 
occupation. 
Individual-level water arsenic publications 
 
Urinary arsenic publications 
(Powers et 
al., 2019) 
 
Longitudinal  
USA 
 
 
n=2132 
Exp: 
Adults 
 
Out: 
Adults 
Male: 
40 
uAs>16.7 
 
vs. 
uAs<5.8 
Cough 
 
 
Dyspnea     
 
All   
 
 
All 
Odds 
ratio 0.78 
 
Odds 
ratio 1.02 
 0.65, 
0.93 
 
 
0.88, 
1.17 
In quartiles. 
Adj: age, sex, 
education, 
site, eGFR, 
tuberculosis, 
and BMI. 
 
3.3.1  Strength of the evidence 
Standardized respiratory symptom questionnaires for the three articles (Nardone et al., 
2017; Siddique et al., 2020; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, 
et al., 2016) were adapted from the British Medical Research Council respiratory questionnaire 
(Cotes, 1987), and the International Union Against Tuberculosis and Lung Disease Bronchial 
Symptoms Questionnaire (Ravault & Kauffmann, 2001). 
Any respiratory symptoms. Two publications were incorporating several respiratory 
symptoms as an inclusive variable (Nardone et al., 2017; Siddique et al., 2020). Although these 
publications included slightly different combinations of symptoms, the positive correlation 
between InAs and “any respiratory symptom” was consistent and statistically significant. In 
(Nardone et al., 2017), the odds of any respiratory symptoms (defined as coughing, wheezing, 
Table 3 (continued) 
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shortness of breath) among high exposure group (>200 μg/L) was 4.07 higher compared to low 
exposure group (<11 μg/L), after adjusting for sex, age, and smoking by categories of arsenic 
exposure and BMI. (Siddique et al., 2020) found high arsenic exposure group (135-1800 μg/L) 
had 2.90 higher odds of any asthma-like symptoms (defined as wheezing, coughs, shortness of 
breath and chest tightness) compared to low exposure group (0.03-5.3 μg/L), after adjusting for 
age, sex, BMI, smoking habits, income, education, and occupation. Exposure assessment was 
based on the presence or absence of skin lesions and residing in either an InAs-endemic or non-
endemic village for at least five years. 
Cough. Three publications evaluated the relationship between InAs and cough (Nardone et 
al., 2017; Powers et al., 2019; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphiné, 
et al., 2016). Publications commonly classified cough by productive/non-productive and 
severity/frequency. In general, InAs was significantly positively correlated with coughing 
symptoms in two of the three publications, and each publication adjusted for potential confounding 
factors, including age, sex, and smoking, etc. (Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, 
Troncoso, Dauphine, et al., 2016) investigated the prevalence of chronic cough in Chilean adults 
exposed to very high levels of early exposure. For the highest single-year exposure, the odds for 
chronic cough among those exposed to wAs >200 μg/L was 12 times the odds among those 
exposed to wAs<11 μg/L after adjusting for age, gender and smoking (95% CI=4.47, 32.0). In 
(Nardone et al., 2017), for single year lifetime highest arsenic exposure, the odds for cough among 
those exposed to wAs>200 μg/L was 10.6 times the odds among those exposed to wAs<11 μg/L 
after adjusting for sex, age, smoking by categories of arsenic exposure and BMI (95% 
CI=3.24,29.2). However, (Powers et al., 2019) found urinary arsenic was inversely associated with 
cough. (Powers et al., 2019) prospectively investigated the relationship between InAs and self-
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reported cough among 2132 American Indian adult participants in the Strong Heart Study. 
Curiously, they found participants in the highest quartile of uAs (>16.7 μg/g creatinine) had lower 
odds of cough compared to participants in the lowest quartile of uAs (<5.8 μg/g creatinine), after 
adjusting for age, sex, education, site, eGFR, tuberculosis and BMI (OR=0.78, 95% CI=0.65,0.93). 
Dyspnea. Three publications examined InAs and a symptom relating to shortness of 
breath/dyspnea (Nardone et al., 2017; Powers et al., 2019; Steinmaus, Ferreccio, Acevedo, Balmes, 
Liaw, Troncoso, Dauphine, et al., 2016). In general, except for one publication (Powers et al., 
2019), the association's direction was consistently positive for all. Two publications used 
standardized questionnaires and graded scales of dyspnea based on different situations (Nardone 
et al., 2017; Powers et al., 2019). (Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, 
Dauphine, et al., 2016) and (Nardone et al., 2017) found participants exposed to high levels of 
wAs had a significant positive association with dyspnea symptoms. (Powers et al., 2019) did not 
correlate arsenic and dyspnea, but positively correlated with stopping for breath while walking 
(OR=1.41, CI= 1.19, 1.69). 
3.3.2  Early life exposure 
Two of the four articles looking at in utero exposure found a statistically significant 
increase in adults' respiratory symptoms (Nardone et al., 2017; Steinmaus, Ferreccio, Acevedo, 
Balmes, Liaw, Troncoso, Dauphine, et al., 2016). Among adults, those exposed to wAs levels >200 
μg/L during ages 0-20 years, had increased odds of shortness of breath, chronic cough, wheeze, 
and asthma compared to adults who were exposed to <11 μg/L during ages 0-20 years (Steinmaus, 
Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016). Among adults, single year 
lifetime highest arsenic exposures>200 μg/L were also associated with increases in cough, 
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shortness of breath, and any symptom when compared to the low exposure group (<11 μg/L). 
Although their exposure indicator was the single highest year, most of the subjects were born 
between 1958 and 1970 (the high exposure period in Antofagasta) and thus had early life exposure 
(Nardone et al., 2017). 
3.3.3  Sex differences 
(Nardone et al., 2017) found the odds ratios for cough, shortness of breath, wheeze, and 
any symptom was greater for females than for males; however, results did not reach statistical 
significance. 
Table 4 Evidence table on InAs and acute respiratory tract infections 
Reference 
Study 
design 
Location 
Size 
Age (yrs) 
Male 
(%) 
Exposure 
level 
Outcome Effect 
estimate 
95%CI/ 
P-value 
Comments 
Ecological- level water arsenic publications 
(Steinmaus, 
Ferreccio, 
Acevedo, 
Balmes, 
Liaw, 
Troncoso, 
Dauphiné, et 
al., 2016) 
 
Cross-
sectional 
Chile 
 
 
n=795 
 
 
 
 
Exp: in 
utero 
 
Out: 
Adults 
Male: 51 
 
 
 
wAs>200 
 
vs. 
wAs<11 
 
 
 
 
 
Child 
hospitalization 
 
 
 
 
 
 
 
Odds 
ratio 
3.94 
 
 
 
 
 
 
 
1.97, 7.87 
 
 
 
 
 
 
 
 
For the 
highest age 0-
20 years. 
Adj: age, 
gender, 
smoking. Ever 
hospitalized 
for a 
respiratory 
infection as a 
child. 
3.4 Acute Respiratory Tract Infections 
 There was one publication on InAs and respiratory tract infections (Steinmaus, Ferreccio, 
Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016) (Table 4). (Steinmaus, Ferreccio, 
Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016) reported a statistically significant 
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increase in child hospitalization (defined as ever hospitalized for a respiratory infection as a child) 
among those exposed to wAs levels >200 μg/L during ages 0-20 years compared to those exposed 
to wAs levels<11 μg/L during ages 0-20 years, after adjusting for age, gender, smoking (OR=3.94, 
CI=1.97, 7.87).  
3.5 Chronic Non-malignant Lung Disease 
Two publications investigated the relationship between InAs and chronic non-malignant 
lung disease (Table 5). The specific disease outcomes include emphysema and chronic bronchitis. 
 
Table 5 Evidence table on InAs an chronic non-malignant lung disease 
Reference 
Study design 
Location 
Size 
Age 
(yrs) 
Male 
(%) 
Exposure 
level 
Outcome Effect 
estimate 
95%CI Comments 
Ecological- level water arsenic publications 
(Steinmaus, 
Ferreccio, 
Acevedo, 
Balmes, Liaw, 
Troncoso, 
Dauphiné, et 
al., 2016) 
 
Cross-sectional 
Chile 
 
 
n=795 
 
 
Exp: in 
utero 
 
Out: 
Adults 
Male: 51 
wAs>200 
 
vs. 
wAs<11 
 
 
Chronic 
bronchitis 
Odds ratio 
2.70 
 
 
 
 
 
0.93, 
7.84 
 
 
 
 
 
For the 
highest age 0-
20 years. 
Adj: age, 
gender, 
smoking.  
 
Individual-level water arsenic publications 
 
Urinary arsenic publications 
 
(Powers et al., 
2019) 
 
 
 
 
USA 
 
 
n=2132 
Exp: 
Adults 
 
Out: 
Adults 
Male:40 
 
uAs>16.7 
 
vs. 
uAs<5.8 
Chronic 
bronchitis 
 
emphysema 
Odds ratio 
1.16 
 
Odds ratio 
1.66 
0.92, 
1.47 
 
1.29, 
2.15 
In quartiles. 
Adj: age, sex, 
education, 
site, eGFR, 
tuberculosis, 
and BMI. 
 
 
22 
3.5.1  Strength of the evidence 
Chronic bronchitis. Two publications investigated the relationship between InAs and 
chronic bronchitis (Powers et al., 2019; Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, 
Dauphine, et al., 2016). (Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphiné, et 
al., 2016) found that among those exposed to wAs levels >200 μg/L during ages 0-20 years had a 
greater risk of chronic bronchitis compared to those exposed to wAs levels <11 μg/L during ages 
0-20 years, after adjusting for age, gender, and smoking, however, results did not reach statistical 
significance (OR=2.70, 95% CI=0.93, 7.84). (Powers et al., 2019) also found a modest association 
(OR=1.16, 95% CI=0.92, 1.47) among uAs and self-reported chronic bronchitis after adjusted for 
age, sex, education, site, eGFR, tuberculosis, and BMI.  
Emphysema. (Powers et al., 2019) also reported greater odds of self-reported emphysema 
among those with the highest quartile of uAs (>16.7 μg/g creatinine) than for those in the lowest 
quartile (<5.8 μg/g creatinine), after adjusting for age, sex, education, site, eGFR, tuberculosis and 
BMI (OR=1.66, 95% CI=1.29,2.15), which was statistically significant. 
3.5.2  Early life exposure 
(Steinmaus, Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphine, et al., 2016) was the 
only publication in this category with exposure assessment in early life (see Section 3.2.2). 
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3.6 Non-malignant lung disease mortality 
None of the eight articles in this review mentioned non-malignant lung disease mortality. 
24 
4.0 Discussion 
For this update, eight studies were incorporated in the review and examined how InAs 
exposure may be related to different aspects of respiratory health, including consistent evidence 
on lung function impairment, respiratory symptoms, and acute respiratory tract infections. This 
review also revealed some common limitations, including an incomplete history of exposure, 
ambiguous outcomes, and limited confounder control. 
4.1 Limitations 
Although there are important discoveries revealed by these studies, there are also 
limitations. Only eight publications on arsenic exposure and non-malignant respiratory illnesses 
met the inclusion criteria. The included studies focused on populations with high levels of arsenic 
exposure (>100 μg/L). Thus, the relationship between arsenic and non-malignant respiratory is 
poorly understood at exposure levels common in the U.S. (<10 μg/L). In about eight percent of 
samples across Pennsylvania, arsenic concentrations met or exceeded the U.S. Environmental 
Protection Agency's maximum pollutant concentration of 10.0 μg/L (Gross, et al., 2013). Further, 
as a systematic review, publication bias is inevitable. Although two complementary databases and 
an intensive gray literature search have been searched, it is inevitable to ignore literature that is 
harder to find, like government reports or unpublished studies. This study was also limited by the 
exclusion of foreign language studies, which caused language bias. During the screening process, 
some publications met the inclusion criteria but were published in Chinese or French, and then 
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they were excluded. The adapted quality assessment questionnaire also has some problems. 
Because the binary quality assessments fail to capture finer details, or authors failed to report the 
required details, the quality of Publications may appear to be higher or lower. Thus, it is necessary 
to be more careful when using quality assessment to evaluate how well a study did. Three of the 
included studies were ecological studies, and the exposure markers are aggregate data rather than 
individual data, making them susceptible to the ecological fallacy. Further, the exposure metric 
(mean arsenic water concentrations for the city) is a comprehensive measurement and does not 
represent the variability in exposure levels within a city. 
4.2 Summary of Findings 
In general, the addition of eight studies did not alter the conclusions drawn by the previous 
systematic review regarding the associations between InAs and respiratory health (Tiffany R 
Sanchez et al., 2016). In terms of lung function, this review found consistent evidence of the 
relationship between increasing InAs and decreasing in FVC and FEV1. This review also found 
consistent evidence of the positive associations between InAs and respiratory symptoms, including 
"any respiratory symptom," cough, and dyspnea. One publication on InAs and respiratory tract 
infections in this review reported a statistically significant positive association between InAs 
exposure and frequency of RTI, consistent with the previous review. Even though two publications 
in this review found a positive association between InAs exposure and chronic non-malignant lung 
disease, including emphysema and chronic bronchitis, the association was not statistically 
significant for chronic bronchitis. Still, the association was statistically significant for emphysema. 
Thus, there was additional evidence to support the relationship between InAs exposure and 
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emphysema. None of the eight articles in this review mentioned non-malignant lung disease 
mortality. Thus, there was no additional evidence to support the relationship between InAs 
exposure and increased non-malignant lung disease mortality. 
Although the results from this systematic review showed that the evidence of a general link 
between InAs and non-malignant respiratory diseases is consistent, the relationship between InAs 
and any single non-malignant respiratory outcome in the pathological process is still poorly 
understood. Arsenic may cause a variety of non-malignant lung diseases through various 
mechanisms, including aberrant wound repair, impaired immune function, and disrupted matrix 
and barrier function. However, the mode of action of these mechanisms in response to arsenic 
exposures and cause non-malignant lung disease is still uncertain and should be further 
investigated. 
This review found consistent evidence of an inverse association between InAs and both 
FEV1 and FVC, but no consistent association for FEV1/FVC. (T. R. Sanchez et al., 2018) also 
found the same relationships. In a restrictive pattern lung function test, FEV1 and FVC are 
generally reduced, but FEV1/FVC is stable or higher. This review provides additional evidence of 
a potential link between arsenic-related lung function defects and restrictive pattern lung disease. 
Determine a specific pattern of lung function defects associated with arsenic exposure that could 
guide future studies aimed at understanding the pathophysiological pathways involved and the 
population at risk. 
Early life exposure. Emerging evidence showed that early life InAs exposure has lasting 
detrimental health effects throughout the lifespan. This review finds that in utero InAs exposure 
leads to adverse respiratory consequences, including lower lung function levels, increased 
respiratory symptoms, and increased child hospitalization due to respiratory infection (Steinmaus, 
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Ferreccio, Acevedo, Balmes, Liaw, Troncoso, Dauphiné, et al., 2016). Evidence on the potential 
effects of arsenic exposure in early adolescence is still lacking. The mechanisms that lead to the 
development of the latent disease is still poorly understood. 
Sex differences. Only three publications in this review described sex differences. In 
general, effect estimates for InAs and lung function seem to be stronger in men than in women, 
consistent with previous studies. (Nardone, Ferreccio et al. 2017) found effect estimates for InAs 
and respiratory symptoms are stronger in women than in men, which is inconsistent with previous 
publications; however, it did not reach statistical significance.  Arsenic metabolism is through a 
series of reduction and methylation reactions. InAs is reduced from pentavalent arsenate (AsV) to 
trivalent arsenite (AsIII), and then the methyl is oxidized to monomethyl arsonic acid(MMA), and 
then the methyl is oxidized to arsonic dimethyl acid (DMA) (Tseng, 2009). The intermediate 
MMA(III) and DMA(III) are highly toxic. Arsenic methylation is influenced by diet, exposure, 
genes, hormones, weight, race, age, and smoking habits. In addition, some studies have reported 
that women excrete more DMA with lower InAs and MMA than men, which indicates that 
women’s overall ability to methylate As increases (Hopenhayn-Rich, Biggs, Smith, Kalman, & 
Moore, 1996; Hsueh et al., 1998; Loffredo, Aposhian, Cebrian, Yamauchi, & Silbergeld, 2003; 
Torres-Sanchez et al., 2016). 
Dosimetry. Although I followed the previous review to perform subgroup analysis on 
lower levels wAs exposure (wAs<100 μg/L), wAs levels in most publications were>100 μg/L; 
thus, the effects of low to moderate arsenic exposures are still unclear. Also, publications used 
different exposure measurement methods and included different exposure comparisons; thus, it is 
difficult to study whether similar exposure levels produce similar effect estimates. 
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5.0 Conclusion 
In this systematic review, eight epidemiological works of literature of different ways of 
InAs related to respiratory health have been updated, to provide evidence for stakeholders in this 
field better and determine future research directions. In brief, the link between InAs and respiratory 
health has been noted throughout the lifespan: in infancy, there is increasing evidence that InAs 
exposure in utero is associated with an increase in the frequency and severity of respiratory tract 
infections; respiratory symptoms also begin to appear in childhood; in adulthood, there is 
consistent evidence that InAs exposure is related with lung function defects (especially FVC) and 
increased reporting of cough and Dyspnea. Common limitations include potential language bias, 
potential publication bias; incomplete exposure histories; ecological fallacy; and the 
incomparability of each publication's measurement outcomes. More research and testing are 
required to better understand the sex differences and low-level dose-response relationship between 
InAs and respiratory health. Early life InAs exposure has lasting detrimental health effects on the 
respiratory system throughout the lifespan. Combined with the previous review, this updated 
review could instruct future research to identify potential relevant pathogenic mechanisms and 
implement effective public health interventions.  
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